Why This Big Buyback Isn't a Long-Term Solution
Edwards Lifesciences announces a $750 million repurchase plan, but is this move ignoring its real problems?
Edwards Lifesciences CFO to Retire
Thomas Abate will step down later this year.
These 4 Stocks Have Held the S&P 500 Back
The S&P has advanced to record highs, but these stocks have fallen dramatically.